-
1
-
-
80053285992
-
Worldwide burden of cervical cancer in 2008
-
Arbyn M., Castellsagué X., de Sanjosé S., Bruni L., Saraiya M., Bray F., et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011, 22:2675-2686.
-
(2011)
Ann Oncol
, vol.22
, pp. 2675-2686
-
-
Arbyn, M.1
Castellsagué, X.2
de Sanjosé, S.3
Bruni, L.4
Saraiya, M.5
Bray, F.6
-
2
-
-
78049485263
-
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
-
Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
-
(2010)
Int J Cancer
, vol.127
, pp. 2893-2917
-
-
Ferlay, J.1
Shin, H.R.2
Bray, F.3
Forman, D.4
Mathers, C.5
Parkin, D.M.6
-
3
-
-
0032840918
-
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
-
Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
-
(1999)
J Pathol
, vol.189
, pp. 12-19
-
-
Walboomers, J.M.1
Jacobs, M.V.2
Manos, M.M.3
Bosch, F.X.4
Kummer, J.A.5
Shah, K.V.6
-
4
-
-
78049528352
-
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
-
de Sanjose S., Quint W.G.V., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11:1048-1056.
-
(2010)
Lancet Oncol
, vol.11
, pp. 1048-1056
-
-
de Sanjose, S.1
Quint, W.G.V.2
Alemany, L.3
Geraets, D.T.4
Klaustermeier, J.E.5
Lloveras, B.6
-
5
-
-
0033518608
-
Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women
-
Palefsky J.M., Minkoff H., Kalish L.A., Levine A., Sacks H.S., Garcia P., et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999, 91:226-236.
-
(1999)
J Natl Cancer Inst
, vol.91
, pp. 226-236
-
-
Palefsky, J.M.1
Minkoff, H.2
Kalish, L.A.3
Levine, A.4
Sacks, H.S.5
Garcia, P.6
-
6
-
-
47749135917
-
Human papillomavirus infection and cervical disease in human immunodeficiency virus-1 infected women
-
Denny L., Boa R., Williamson A.L., Allan B., Hardie D., Ress S., et al. Human papillomavirus infection and cervical disease in human immunodeficiency virus-1 infected women. Obstet Gynecol 2008, 111:1380-1387.
-
(2008)
Obstet Gynecol
, vol.111
, pp. 1380-1387
-
-
Denny, L.1
Boa, R.2
Williamson, A.L.3
Allan, B.4
Hardie, D.5
Ress, S.6
-
7
-
-
50649110466
-
Association between invasive cancer of the cervix and HIV-1 infection in Tanzania: the need for dual screening
-
Kahesa C., Mwaiselage J., Wabinga H.R., Ngoma T., Kalyango J.N., Karamagi C.A. Association between invasive cancer of the cervix and HIV-1 infection in Tanzania: the need for dual screening. BMC Public Health 2008, 8:262.
-
(2008)
BMC Public Health
, vol.8
, pp. 262
-
-
Kahesa, C.1
Mwaiselage, J.2
Wabinga, H.R.3
Ngoma, T.4
Kalyango, J.N.5
Karamagi, C.A.6
-
8
-
-
67650458435
-
Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women
-
Singh D.K., Anastos K., Hoover D.R., Burk R.D., Shi Q., Ngendahayo L., et al. Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. J Infect Dis 2009, 199:1851-1861.
-
(2009)
J Infect Dis
, vol.199
, pp. 1851-1861
-
-
Singh, D.K.1
Anastos, K.2
Hoover, D.R.3
Burk, R.D.4
Shi, Q.5
Ngendahayo, L.6
-
9
-
-
77955543756
-
Assessing the relationship between HIV infection and cervical cancer in Cote d'Ivoire: a case-control study
-
Adjorlolo-Johnson G., Unger E.R., Boni-Ouattara E., Touré-Coulibaly K., Maurice C., Vernon S.D., et al. Assessing the relationship between HIV infection and cervical cancer in Cote d'Ivoire: a case-control study. BMC Infect Dis 2010, 10:242.
-
(2010)
BMC Infect Dis
, vol.10
, pp. 242
-
-
Adjorlolo-Johnson, G.1
Unger, E.R.2
Boni-Ouattara, E.3
Touré-Coulibaly, K.4
Maurice, C.5
Vernon, S.D.6
-
10
-
-
74049123602
-
Association of oncogenic and nononcogenic human papillomavirus with HIV incidence
-
Auvert B., Lissouba P., Cutler E., Zarca K., Puren A., Taljaard D. Association of oncogenic and nononcogenic human papillomavirus with HIV incidence. J Acquir Immune Defic Syndr 2010, 53:111-116.
-
(2010)
J Acquir Immune Defic Syndr
, vol.53
, pp. 111-116
-
-
Auvert, B.1
Lissouba, P.2
Cutler, E.3
Zarca, K.4
Puren, A.5
Taljaard, D.6
-
11
-
-
84886946976
-
-
UNAIDS Report on the Global AIDS Epidemic [accessed 11.7.12].
-
UNAIDS Report on the Global AIDS Epidemic 2010. [accessed 11.7.12]. http://www.unaids.org/globalreport/Global_report.htm.
-
-
-
-
12
-
-
33745290276
-
HIV and pre-neoplastic and neoplastic lesions of the cervix in South Africa: a case-control study
-
Moodley J.R., Hoffman M., Carrara H., Allan B.R., Cooper D.D., Rosenberg L., et al. HIV and pre-neoplastic and neoplastic lesions of the cervix in South Africa: a case-control study. BMC Cancer 2006, 6:135.
-
(2006)
BMC Cancer
, vol.6
, pp. 135
-
-
Moodley, J.R.1
Hoffman, M.2
Carrara, H.3
Allan, B.R.4
Cooper, D.D.5
Rosenberg, L.6
-
13
-
-
8444249386
-
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
-
Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364:1757-1765.
-
(2004)
Lancet
, vol.364
, pp. 1757-1765
-
-
Harper, D.M.1
Franco, E.L.2
Wheeler, C.3
Ferris, D.G.4
Jenkins, D.5
Schuind, A.6
-
14
-
-
33646058566
-
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
-
Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367:1247-1255.
-
(2006)
Lancet
, vol.367
, pp. 1247-1255
-
-
Harper, D.M.1
Franco, E.L.2
Wheeler, C.M.3
Moscicki, A.B.4
Romanowski, B.5
Roteli-Martins, C.M.6
-
15
-
-
34250850161
-
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial
-
Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmerón J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369:2161-2170.
-
(2007)
Lancet
, vol.369
, pp. 2161-2170
-
-
Paavonen, J.1
Jenkins, D.2
Bosch, F.X.3
Naud, P.4
Salmerón, J.5
Wheeler, C.M.6
-
16
-
-
67651049056
-
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
-
Paavonen J., Naud P., Salmerón J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
-
(2009)
Lancet
, vol.374
, pp. 301-314
-
-
Paavonen, J.1
Naud, P.2
Salmerón, J.3
Wheeler, C.M.4
Chow, S.N.5
Apter, D.6
-
17
-
-
71649087760
-
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years
-
GlaxoSmithKline Vaccine HPV-007 Study Group
-
GlaxoSmithKline Vaccine HPV-007 Study Group Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009, 374:1975-1985.
-
(2009)
Lancet
, vol.374
, pp. 1975-1985
-
-
-
18
-
-
84855300842
-
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
-
Lehtinen M., Paavonen J., Wheeler C.M., Jaisamrarn U., Garland S.M., Castellsagué X., et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:89-99.
-
(2012)
Lancet Oncol
, vol.13
, pp. 89-99
-
-
Lehtinen, M.1
Paavonen, J.2
Wheeler, C.M.3
Jaisamrarn, U.4
Garland, S.M.5
Castellsagué, X.6
-
19
-
-
84855309413
-
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
-
Wheeler C.M., Castellsagué X., Garland S.M., Szarewski A., Paavonen J., Naud P., et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:100-110.
-
(2012)
Lancet Oncol
, vol.13
, pp. 100-110
-
-
Wheeler, C.M.1
Castellsagué, X.2
Garland, S.M.3
Szarewski, A.4
Paavonen, J.5
Naud, P.6
-
20
-
-
84886954027
-
-
WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. World Health Organization
-
WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. World Health Organization, 2007.
-
(2007)
-
-
-
21
-
-
84886950890
-
-
Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. World Health Organization
-
Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. World Health Organization, 2006.
-
(2006)
-
-
-
22
-
-
84886950785
-
-
Provincial Administration Western Cape. Antiretroviral Treatment Protocol. Version 2, April
-
Provincial Administration Western Cape. Antiretroviral Treatment Protocol. Version 2, April 2004.
-
(2004)
-
-
-
23
-
-
56149091686
-
Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine
-
Dessy F.J., Giannini S.L., Bougelet C.A., Kemp T.J., David M.P., Poncelet S.M., et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccine 2008, 4:425-434.
-
(2008)
Hum Vaccine
, vol.4
, pp. 425-434
-
-
Dessy, F.J.1
Giannini, S.L.2
Bougelet, C.A.3
Kemp, T.J.4
David, M.P.5
Poncelet, S.M.6
-
24
-
-
84855181757
-
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years
-
Einstein M.H., Baron M., Levin M.J., Chatterjee A., Fox B., Scholar S., et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccine 2011, 7:1343-1358.
-
(2011)
Hum Vaccine
, vol.7
, pp. 1343-1358
-
-
Einstein, M.H.1
Baron, M.2
Levin, M.J.3
Chatterjee, A.4
Fox, B.5
Scholar, S.6
-
25
-
-
67651031934
-
Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention. A pooled analysis of 11 clinical trials
-
Descamps D., Hardt K., Spiessens B., Izurieta P., Verstraeten T., Breuer T., et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention. A pooled analysis of 11 clinical trials. Hum Vaccin 2009, 5:332-340.
-
(2009)
Hum Vaccin
, vol.5
, pp. 332-340
-
-
Descamps, D.1
Hardt, K.2
Spiessens, B.3
Izurieta, P.4
Verstraeten, T.5
Breuer, T.6
-
26
-
-
70049106412
-
Non-responsiveness to hepatitis B vaccination in HIV seropositive patients; possible causes and solutions
-
van den Berg R., van Hoogstraten I., van Agtmael M. Non-responsiveness to hepatitis B vaccination in HIV seropositive patients; possible causes and solutions. AIDS Rev 2009, 11:157-164.
-
(2009)
AIDS Rev
, vol.11
, pp. 157-164
-
-
van den Berg, R.1
van Hoogstraten, I.2
van Agtmael, M.3
-
27
-
-
35349028297
-
GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives
-
Garçon N., Chomez P., Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007, 6:723-739.
-
(2007)
Expert Rev Vaccines
, vol.6
, pp. 723-739
-
-
Garçon, N.1
Chomez, P.2
Van Mechelen, M.3
-
28
-
-
0029201182
-
Monophosphoryl lipid A as an adjuvant, Past experiences and new directions
-
Ulrich J.T., Myers K.R. Monophosphoryl lipid A as an adjuvant, Past experiences and new directions. Pharm Biotechnol 1995, 6:495-524.
-
(1995)
Pharm Biotechnol
, vol.6
, pp. 495-524
-
-
Ulrich, J.T.1
Myers, K.R.2
-
29
-
-
0037654784
-
Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529
-
Evans J.T., Cluff C.W., Johnson D.A., Lacy M.J., Persing D.H., Baldridge J.R. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vaccines 2003, 2:219-229.
-
(2003)
Expert Rev Vaccines
, vol.2
, pp. 219-229
-
-
Evans, J.T.1
Cluff, C.W.2
Johnson, D.A.3
Lacy, M.J.4
Persing, D.H.5
Baldridge, J.R.6
-
30
-
-
33746096523
-
Enhanced humoral and memory B-cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminum salt combination (AS04) compared to aluminum salt only
-
Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B-cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminum salt combination (AS04) compared to aluminum salt only. Vaccine 2006, 24:5937-5949.
-
(2006)
Vaccine
, vol.24
, pp. 5937-5949
-
-
Giannini, S.L.1
Hanon, E.2
Moris, P.3
Van Mechelen, M.4
Morel, S.5
Dessy, F.6
|